These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 8406274)
21. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Kardas P Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016 [TBL] [Abstract][Full Text] [Related]
22. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M; Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789 [TBL] [Abstract][Full Text] [Related]
23. The interaction of mofebutazone with furosemide. Matthei U; Grabensee B; Loew D Curr Med Res Opin; 1987; 10(9):638-44. PubMed ID: 3481307 [TBL] [Abstract][Full Text] [Related]
24. [Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months]. D'Argenzio R; Cavallo P; Merante D; Morelli A Minerva Endocrinol; 1996 Sep; 21(3):101-10. PubMed ID: 9072666 [TBL] [Abstract][Full Text] [Related]
25. The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. Mück W; Heine PR; Breuel HP; Niklaus H; Horkulak J; Ahr G Int J Clin Pharmacol Ther; 1995 Feb; 33(2):89-94. PubMed ID: 7757317 [TBL] [Abstract][Full Text] [Related]
26. Delayed-type hypersensitivity to mofebutazone underlying a severe drug reaction. Walchner M; Rueff F; Przybilla B Contact Dermatitis; 1997 Jan; 36(1):54-5. PubMed ID: 9034692 [No Abstract] [Full Text] [Related]
27. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes]. Ledermann H; Höxter G Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886 [TBL] [Abstract][Full Text] [Related]
28. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus. Waysbort J; Regitz G; Chaimowitz D; Tuval M; Nakash I; Brunner D Clin Ther; 1988; 10(4):358-71. PubMed ID: 2978874 [TBL] [Abstract][Full Text] [Related]
29. [Combination treatment of insulin dependent elderly diabetics (type II diabetes) with the sulfonylurea compound glibenclamide]. Naurath HJ; Füsgen I Z Gerontol; 1985; 18(5):302-4. PubMed ID: 3934860 [TBL] [Abstract][Full Text] [Related]
30. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914 [TBL] [Abstract][Full Text] [Related]
32. Structure of phenylbutazone and mofebutazone in the crystalline state and in solution. Paradies HH J Pharm Sci; 1987 Dec; 76(12):920-9. PubMed ID: 3440938 [TBL] [Abstract][Full Text] [Related]
33. A monitored-release study of methrazone in general practice. Harris PG J Int Med Res; 1980; 8(4):276-82. PubMed ID: 6447635 [TBL] [Abstract][Full Text] [Related]
34. High-resolution solid-state carbon-13 nuclear magnetic resonance spectra of mofebutazone, phenylbutazone, and oxyphenbutazone in relation to X-ray crystallographic data. Stoltz M; Oliver DW; Wessels PL; Chalmers AA J Pharm Sci; 1991 Apr; 80(4):357-62. PubMed ID: 1865336 [TBL] [Abstract][Full Text] [Related]
35. Adverse effect on diabetes control of concomitant glibenclamide and tolbutamide. Katsumata K; Katsumata Y Lancet; 1991 Mar; 337(8741):614. PubMed ID: 1671966 [No Abstract] [Full Text] [Related]
36. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Brouwers JR; de Smet PA Clin Pharmacokinet; 1994 Dec; 27(6):462-85. PubMed ID: 7882636 [TBL] [Abstract][Full Text] [Related]
37. [Mofebutazone--evaluation of possible interaction with glibenclamide]. Speders S Fortschr Med; 1993 Aug; 111(22-23):366-8. PubMed ID: 8406274 [TBL] [Abstract][Full Text] [Related]
38. [Interactions of non-steroidal antirheumatic drugs with oral antidiabetic agents: acemetacin--glibenclamide]. Haupt E; Hoppe FK; Rechziegler H; Zündorf P Z Rheumatol; 1987; 46(4):170-3. PubMed ID: 3118589 [TBL] [Abstract][Full Text] [Related]
39. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Rosak C; Haupt E; Walter T; Werner J Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728 [TBL] [Abstract][Full Text] [Related]
40. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients. Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]